Literature DB >> 12048679

[Detection of fibroblast growth factor receptor 3 gene mutation at nucleotide 1138 site in congenita achondroplasia patients].

Jihong Ni1, Guoqiang Lu, Wei Wang, Fengsheng Chen, Huili Qin, Defen Wang.   

Abstract

OBJECTIVE: [corrected] To investigate the mutation at the transmembrane domain of fibroblast growth factor receptor 3 (FGFR3) nucleotide 1138 site for identifying the major pathologic mechanism of achondroplasia (ACH) and to evaluate the efficacy of denaturing gradient gel electrophoresis(DGGE) method for screening the point mutations.
METHODS: The genomic DNA from 17 clinically diagnosed ACH patients where analysed by polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP) with Sfc I and Msp I restriction endonucleases and by PCR-DGGE technique for screening.
RESULTS: G to A transition mutation at nucleotide 1138 was detected in 14/17 of the ACH patients as heterozygotes by PCR-RFLP with Sfc I digestion. No 1138 G to C transition was detected by Msp I digestion. All of the 14 samples with G to A mutation were also found to be positive for point mutation by PCR-DGGE. No mutation was detected in 3 negative samples by PCR-RFLP, implying that there was actually no point mutation in this amplified region.
CONCLUSION: Nucleotide 1138 in transmembrane domain of FGFR3 gene is the hot point for mutation in ACH and hence its major pathologic cause. PCR-DGGE is a sensitive and reliable technique for point mutation screening, especially for the heterozygotes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12048679

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Yi Chuan Xue Za Zhi        ISSN: 1003-9406


  1 in total

1.  The population-based prevalence of achondroplasia and thanatophoric dysplasia in selected regions of the US.

Authors:  D K Waller; A Correa; Tuan M Vo; Y Wang; C Hobbs; P H Langlois; K Pearson; P A Romitti; G M Shaw; J T Hecht
Journal:  Am J Med Genet A       Date:  2008-09-15       Impact factor: 2.802

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.